Vanda Pharmaceuticals (VNDA)
(Delayed Data from NSDQ)
$4.62 USD
+0.14 (3.13%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.61 -0.01 (-0.22%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
VNDA 4.62 +0.14(3.13%)
Will VNDA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VNDA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VNDA
Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
VNDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up
Investors Heavily Search Vanda Pharmaceuticals Inc. (VNDA): Here is What You Need to Know
Vanda Pharmaceuticals (VNDA) Declines More Than Market: Some Information for Investors
Other News for VNDA
Vanda Pharmaceuticals (VNDA) Shares Cross Below 200 DMA
Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
Shareholder Capital delivers letter to board of Vanda Pharmaceuticals
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZĀ® ANDA Litigation
US Supreme Court reportedly declines to hear Vanda patent case